{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:01:47Z","timestamp":1787238107922,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00796-w","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T10:58:36Z","timestamp":1754391516000},"page":"2063-2081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management"],"prefix":"10.1007","volume":"14","author":[{"given":"Renato","family":"Mantegazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Polistena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"796_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2570\u201381. https:\/\/doi.org\/10.1056\/NEJMra1602678.","journal-title":"N Engl J Med"},{"key":"796_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3.","journal-title":"Lancet Neurol"},{"key":"796_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. https:\/\/doi.org\/10.1186\/1471-2377-10-46.","journal-title":"BMC Neurol"},{"key":"796_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118340","author":"G Antonini","year":"2021","unstructured":"Antonini G, Habetswallner F, Inghilleri M, et al. Estimation of myasthenia gravis prevalence in Italy using real-world data. J Neurol Sci. 2021. https:\/\/doi.org\/10.1016\/j.jns.2021.118340.","journal-title":"J Neurol Sci"},{"key":"796_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.605902","volume":"11","author":"A Evoli","year":"2020","unstructured":"Evoli A, Iorio R. Controversies in ocular Myasthenia Gravis. Front Neurol. 2020;11: 605902. https:\/\/doi.org\/10.3389\/fneur.2020.605902.","journal-title":"Front Neurol"},{"key":"796_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/088307389300800422","volume":"8","author":"AK Afifi","year":"1993","unstructured":"Afifi AK, Bell WE. Tests for juvenile myasthenia gravis: comparative diagnostic yield and prediction of outcome. J Child Neurol. 1993;8:403\u201311. https:\/\/doi.org\/10.1177\/088307389300800422.","journal-title":"J Child Neurol"},{"key":"796_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli A, Antonini G, Antozzi C, et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci. 2019;40:1111\u201324. https:\/\/doi.org\/10.1007\/s10072-019-03746-1.","journal-title":"Neurol Sci"},{"key":"796_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091286","volume":"13","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Lupica A, et al. Diagnosis and management of seronegative Myasthenia gravis: lights and shadows. Brain Sci. 2023;13: 1286. https:\/\/doi.org\/10.3390\/brainsci13091286.","journal-title":"Brain Sci"},{"key":"796_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","volume":"80","author":"F Baggi","year":"2013","unstructured":"Baggi F, Andreetta F, Maggi L, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80:188\u201395. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b907b.","journal-title":"Neurology"},{"key":"796_CR10","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242.","journal-title":"Ther Adv Neurol Disord"},{"key":"796_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16367","volume":"9","author":"G Antonini","year":"2023","unstructured":"Antonini G, Habetswallner F, Inghilleri M, et al. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. 2023;9: e16367. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367.","journal-title":"Heliyon"},{"key":"796_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43:428\u201335. https:\/\/doi.org\/10.3109\/08916930903518107.","journal-title":"Autoimmunity"},{"key":"796_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/NDT.S8915","volume":"7","author":"R Mantegazza","year":"2011","unstructured":"Mantegazza R, Bonanno S, Camera G, Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 2011;7:151\u201360. https:\/\/doi.org\/10.2147\/NDT.S8915.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"796_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018;36:311\u201337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011.","journal-title":"Neurol Clin"},{"key":"796_CR15","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39:2216\u201329. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.011.","journal-title":"Clin Ther"},{"key":"796_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","volume":"30","author":"MR Tannemaat","year":"2020","unstructured":"Tannemaat MR, Verschuuren JJGM. Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids. Neuromuscul Disord. 2020;30:111\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2019.12.003.","journal-title":"Neuromuscul Disord"},{"key":"796_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10072-016-2556-3","volume":"37","author":"D Cioncoloni","year":"2016","unstructured":"Cioncoloni D, Casali S, Ginanneschi F, et al. Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients. Neurol Sci. 2016;37:717\u201323. https:\/\/doi.org\/10.1007\/s10072-016-2556-3.","journal-title":"Neurol Sci"},{"key":"796_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","volume":"7","author":"Y Nagane","year":"2017","unstructured":"Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7: e013278. https:\/\/doi.org\/10.1136\/bmjopen-2016-013278.","journal-title":"BMJ Open"},{"key":"796_CR19","first-page":"173","volume":"41","author":"M Katsuki","year":"2020","unstructured":"Katsuki M, Sugahara H, Kojima Y, et al. Comparison of quality of life and activity of daily living status of patients with myasthenia gravis treated with low-dose and high- dose prednisolone. Neuro Endocrinol Lett. 2020;41:173\u20138.","journal-title":"Neuro Endocrinol Lett"},{"key":"796_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology"},{"key":"796_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of Myasthenia gravis: 2020 update. Neurology. 2021;96:114\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"key":"796_CR22","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"key":"796_CR23","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1097\/WNO.0000000000001058","volume":"41","author":"YS Shah","year":"2021","unstructured":"Shah YS, Henderson AD, Carey AR. Effect of initial prednisone dosing on ocular Myasthenia gravis control. J Neuroophthalmol. 2021;41:e622\u20136. https:\/\/doi.org\/10.1097\/WNO.0000000000001058.","journal-title":"J Neuroophthalmol"},{"key":"796_CR24","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296","author":"S Johnson","year":"2021","unstructured":"Johnson S, Katyal N, Narula N, Govindarajan R. Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized Myasthenia gravis. Med Sci Monit. 2021. https:\/\/doi.org\/10.12659\/MSM.933296.","journal-title":"Med Sci Monit"},{"key":"796_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117274","volume":"420","author":"R Verma","year":"2021","unstructured":"Verma R, Wolfe GI, Kupersmith MJ. Ocular myasthenia gravis\u2014how effective is low dose prednisone long term? J Neurol Sci. 2021;420: 117274. https:\/\/doi.org\/10.1016\/j.jns.2020.117274.","journal-title":"J Neurol Sci"},{"key":"796_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, Mcdermott MP, Sanders DB, et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016;53:363\u20139. https:\/\/doi.org\/10.1002\/mus.24769.","journal-title":"Muscle Nerve"},{"key":"796_CR27","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2147\/OPTH.S261259","volume":"14","author":"T Threetong","year":"2020","unstructured":"Threetong T, Poonyathalang A, Preechawat P, et al. Initial treatment response in ocular Myasthenia gravis: a comparison between low and moderate doses of prednisolone. Clin Ophthalmol. 2020;14:2051\u20136. https:\/\/doi.org\/10.2147\/OPTH.S261259.","journal-title":"Clin Ophthalmol"},{"key":"796_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08164622.2022.2029683","volume":"105","author":"NH Shuey","year":"2022","unstructured":"Shuey NH. Ocular myasthenia gravis: a review and practical guide for clinicians. Clin Exp Optom. 2022;105:205\u201313. https:\/\/doi.org\/10.1080\/08164622.2022.2029683.","journal-title":"Clin Exp Optom"},{"key":"796_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194393","volume":"10","author":"C-C Chang","year":"2021","unstructured":"Chang C-C, Yeh J-H, Chen Y-M, et al. Clinical predictors of prolonged hospital stay in patients with Myasthenia gravis: a study using machine learning algorithms. J Clin Med. 2021;10: 4393. https:\/\/doi.org\/10.3390\/jcm10194393.","journal-title":"J Clin Med"},{"key":"796_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/jnnp.2004.038430","volume":"76","author":"M Llabr\u00e9s","year":"2005","unstructured":"Llabr\u00e9s M, Molina-Martinez FJ, Miralles F. Dysphagia as the sole manifestation of Myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005;76:1297\u2013300. https:\/\/doi.org\/10.1136\/jnnp.2004.038430.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"796_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in Myasthenia gravis. N Engl J Med. 2016;375:511\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1602489.","journal-title":"N Engl J Med"},{"key":"796_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jocn.2021.03.015","volume":"88","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Wang M, Xu L, et al. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: a systematic review and meta-analysis. Clin Neurosci. 2021;88:70\u20134. https:\/\/doi.org\/10.1016\/j.jocn.2021.03.015.","journal-title":"Clin Neurosci"},{"key":"796_CR33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cns.13468","volume":"26","author":"C Zhang","year":"2020","unstructured":"Zhang C, Bu B, Yang H, et al. Immunotherapy choice and maintenance for generalized myasthenia gravis in China. CNS Neurosci Ther. 2020;26:1241\u201354. https:\/\/doi.org\/10.1111\/cns.13468.","journal-title":"CNS Neurosci Ther"},{"key":"796_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.816243","volume":"13","author":"S Su","year":"2022","unstructured":"Su S, Lei L, Fan Z, et al. Clinical predictors of relapse in a cohort of steroid- treated patients with well-controlled myasthenia gravis. Front Neurol. 2022;13: 816243. https:\/\/doi.org\/10.3389\/fneur.2022.816243.","journal-title":"Front Neurol"},{"key":"796_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/wnl.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, et al. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984;34:170\u20134. https:\/\/doi.org\/10.1212\/wnl.34.2.170.","journal-title":"Neurology"},{"key":"796_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030932","volume":"101","author":"S Fukui","year":"2022","unstructured":"Fukui S, Nakai T, Kawaai S, et al. Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: a preliminary retrospective cohort study. Medicine (Baltimore). 2022;101: e30932. https:\/\/doi.org\/10.1097\/MD.0000000000030932.","journal-title":"Medicine (Baltimore)"},{"key":"796_CR37","unstructured":"(2022) Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, 14e | AccessMedicine | McGraw Hill Medical. https:\/\/accessmedicine.mhmedical.com\/book.aspx?bookID=3191. Accessed 18 Jul 2022"},{"key":"796_CR38","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1007\/s00415-021-10544-3","volume":"268","author":"A Wilf-Yarkoni","year":"2021","unstructured":"Wilf-Yarkoni A, Lotan I, Steiner I, Hellmann MA. Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis. J Neurol. 2021;268:3871\u20137. https:\/\/doi.org\/10.1007\/s00415-021-10544-3.","journal-title":"J Neurol"},{"key":"796_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis\u2014opinions and a review of the literature. Front Neurol. 2020. https:\/\/doi.org\/10.3389\/fneur.2020.00604.","journal-title":"Front Neurol"},{"key":"796_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","volume":"11","author":"K O\u2019Connell","year":"2020","unstructured":"O\u2019Connell K, Ramdas S, Palace J. Management of juvenile myasthenia gravis. Front Neurol. 2020;11:743. https:\/\/doi.org\/10.3389\/fneur.2020.00743.","journal-title":"Front Neurol"},{"key":"796_CR41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3389\/fneur.2020.00554","volume":"11","author":"NE Gilhus","year":"2020","unstructured":"Gilhus NE. Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol. 2020;11:554. https:\/\/doi.org\/10.3389\/fneur.2020.00554.","journal-title":"Front Neurol"},{"key":"796_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2373\/S0026-4784.20.04505-0","volume":"72","author":"MG Piccioni","year":"2020","unstructured":"Piccioni MG, Tabacco S, Giannini A, et al. Myasthaenia gravis in pregnancy, delivery and newborn. Minerva Ginecol. 2020;72:30\u20135. https:\/\/doi.org\/10.2373\/S0026-4784.20.04505-0.","journal-title":"Minerva Ginecol"},{"key":"796_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00198-021-06101-3","volume":"33","author":"Z Safipour","year":"2022","unstructured":"Safipour Z, van der Zanden R, van den Bergh J, et al. The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis. Osteoporos Int. 2022;33:649\u201358. https:\/\/doi.org\/10.1007\/s00198-021-06101-3.","journal-title":"Osteoporos Int"},{"key":"796_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae043","author":"H-S Park","year":"2024","unstructured":"Park H-S, Kim K, Yu MH, et al. Risk of fracture in patients with myasthenia gravis: a nationwide cohort study in Korea. J Bone Miner Res. 2024. https:\/\/doi.org\/10.1093\/jbmr\/zjae043.","journal-title":"J Bone Miner Res"},{"key":"796_CR45","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","volume":"268","author":"I Lotan","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, et al. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. 2021;268:4573\u201386. https:\/\/doi.org\/10.1007\/s00415-020-10264-0.","journal-title":"J Neurol"},{"key":"796_CR46","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1007\/s10072-022-05897-0","volume":"43","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li F, Zhu H, et al. Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy. Neurol Sci. 2022;43:3949\u201356. https:\/\/doi.org\/10.1007\/s10072-022-05897-0.","journal-title":"Neurol Sci"},{"key":"796_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of Myasthenia gravis. J Clin Med. 2022;11: 1597. https:\/\/doi.org\/10.3390\/jcm11061597.","journal-title":"J Clin Med"},{"key":"796_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/mus.25095","volume":"54","author":"AC Braga","year":"2016","unstructured":"Braga AC, Pinto C, Santos E, Braga J. Myasthenia gravis in pregnancy: experience of a Portuguese center. Muscle Nerve. 2016;54:715\u201320. https:\/\/doi.org\/10.1002\/mus.25095.","journal-title":"Muscle Nerve"},{"key":"796_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","volume":"78","author":"T Sharshar","year":"2021","unstructured":"Sharshar T, Porcher R, Demeret S, et al. Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2021;78:426\u201333. https:\/\/doi.org\/10.1001\/jamaneurol.2020.5407.","journal-title":"JAMA Neurol"},{"key":"796_CR50","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","volume":"43","author":"G Bandoli","year":"2017","unstructured":"Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43:489\u2013502. https:\/\/doi.org\/10.1016\/j.rdc.2017.04.013.","journal-title":"Rheum Dis Clin North Am"},{"key":"796_CR51","doi-asserted-by":"publisher","first-page":"13497","DOI":"10.1038\/s41598-020-70539-4","volume":"10","author":"L D\u00edez-Porras","year":"2020","unstructured":"D\u00edez-Porras L, Homedes C, Alberti MA, et al. Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis. Sci Rep. 2020;10:13497. https:\/\/doi.org\/10.1038\/s41598-020-70539-4.","journal-title":"Sci Rep"},{"key":"796_CR52","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1744666X.2021.1936500","volume":"17","author":"A Evoli","year":"2021","unstructured":"Evoli A, Spagni G, Monte G, Damato V. Heterogeneity in myasthenia gravis: considerations for disease management. Expert Rev Clin Immunol. 2021;17:761\u201371. https:\/\/doi.org\/10.1080\/1744666X.2021.1936500.","journal-title":"Expert Rev Clin Immunol"},{"key":"796_CR53","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JND-200584","volume":"8","author":"N Katyal","year":"2021","unstructured":"Katyal N, Narula N, Govindarajan R. Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neuromuscul Dis. 2021;8:287\u201394. https:\/\/doi.org\/10.3233\/JND-200584.","journal-title":"J Neuromuscul Dis"},{"key":"796_CR54","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22:383\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7.","journal-title":"Lancet Neurol"},{"key":"796_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733418","volume":"12","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Zhou R, Yang H, Yang H. To be or not to be vaccinated: that is a question in myasthenia gravis. Front Immunol. 2021;12: 733418. https:\/\/doi.org\/10.3389\/fimmu.2021.733418.","journal-title":"Front Immunol"},{"key":"796_CR56","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21440","volume":"40","author":"L Zinman","year":"2009","unstructured":"Zinman L, Thoma J, Kwong JC, et al. Safety of influenza vaccination in patients with myasthenia gravis: a population-based study. Muscle Nerve. 2009;40:947\u201351. https:\/\/doi.org\/10.1002\/mus.21440.","journal-title":"Muscle Nerve"},{"key":"796_CR57","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1093\/cid\/ciac404","volume":"76","author":"P Corradini","year":"2023","unstructured":"Corradini P, Agrati C, Apolone G, et al. Humoral and T-cell immune response after 3 doses of messenger RNA severe acute respiratory syndrome coronavirus 2 vaccines in fragile patients: the Italian VAX4FRAIL study. Clin Infect Dis. 2023;76:e426\u201338. https:\/\/doi.org\/10.1093\/cid\/ciac404.","journal-title":"Clin Infect Dis"},{"key":"796_CR58","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200002","volume":"9","author":"D Reyes-Leiva","year":"2022","unstructured":"Reyes-Leiva D, L\u00f3pez-Contreras J, Moga E, et al. Immune response and safety of SARS-CoV-2 mRNA-1273 vaccine in patients with myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2022;9: e200002. https:\/\/doi.org\/10.1212\/NXI.0000000000200002.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"796_CR59","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1016\/j.vaccine.2014.09.003","volume":"32","author":"S Esposito","year":"2014","unstructured":"Esposito S, Bruno C, Berardinelli A, et al. Vaccination recommendations for patients with neuromuscular disease. Vaccine. 2014;32:5893\u2013900. https:\/\/doi.org\/10.1016\/j.vaccine.2014.09.003.","journal-title":"Vaccine"},{"key":"796_CR60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5588\/ijtld.12.0260","volume":"17","author":"S-M Ou","year":"2013","unstructured":"Ou S-M, Liu C-J, Chang Y-S, et al. Tuberculosis in myasthenia gravis. Int J Tuberc Lung Dis. 2013;17:79\u201384. https:\/\/doi.org\/10.5588\/ijtld.12.0260.","journal-title":"Int J Tuberc Lung Dis"},{"key":"796_CR61","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12883-019-1482-4","volume":"19","author":"S Wang","year":"2019","unstructured":"Wang S, Jiang B, Li Y, et al. A case report of disseminated nocardiosis with ocular involvement in a myasthenia gravis patient and literature review. BMC Neurol. 2019;19:243. https:\/\/doi.org\/10.1186\/s12883-019-1482-4.","journal-title":"BMC Neurol"},{"key":"796_CR62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12879-018-3378-0","volume":"18","author":"MN Chitasombat","year":"2018","unstructured":"Chitasombat MN, Ratchatanawin N, Visessiri Y. Disseminated extrapulmonary Legionella pneumophila infection presenting with panniculitis: case report and literature review. BMC Infect Dis. 2018;18:467. https:\/\/doi.org\/10.1186\/s12879-018-3378-0.","journal-title":"BMC Infect Dis"},{"key":"796_CR63","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mus.26032","volume":"57","author":"DE Prior","year":"2018","unstructured":"Prior DE, Nurre E, Roller SL, et al. Infections and the relationship to treatment in neuromuscular autoimmunity. Muscle Nerve. 2018;57:927\u201331. https:\/\/doi.org\/10.1002\/mus.26032.","journal-title":"Muscle Nerve"},{"key":"796_CR64","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","volume":"37","author":"E Strijbos","year":"2019","unstructured":"Strijbos E, Tannemaat MR, Alleman I, et al. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine. 2019;37:919\u201325. https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.007.","journal-title":"Vaccine"},{"key":"796_CR65","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.nmd.2021.05.006","volume":"31","author":"AM Ruiter","year":"2021","unstructured":"Ruiter AM, Strijbos E, de Meel RHP, et al. Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome. Neuromuscul Disord. 2021;31:622\u201332. https:\/\/doi.org\/10.1016\/j.nmd.2021.05.006.","journal-title":"Neuromuscul Disord"},{"key":"796_CR66","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/mus.24213","volume":"50","author":"K Utsugisawa","year":"2014","unstructured":"Utsugisawa K, Suzuki S, Nagane Y, et al. Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve. 2014;50:493\u2013500. https:\/\/doi.org\/10.1002\/mus.24213.","journal-title":"Muscle Nerve"},{"key":"796_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126579","volume":"10","author":"S Konno","year":"2015","unstructured":"Konno S, Suzuki S, Masuda M, et al. Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study. PLoS One. 2015;10: e0126579. https:\/\/doi.org\/10.1371\/journal.pone.0126579.","journal-title":"PLoS One"},{"key":"796_CR68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/WNO.0b013e3182536558","volume":"32","author":"BB Bruce","year":"2012","unstructured":"Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. J Neuroophthalmol. 2012;32:212\u20135. https:\/\/doi.org\/10.1097\/WNO.0b013e3182536558.","journal-title":"J Neuroophthalmol"},{"key":"796_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, et al. Myasthenia gravis: association of British neurologists\u2019 management guidelines. Pract Neurol. 2015;15:199\u2013206. https:\/\/doi.org\/10.1136\/practneurol-2015-001126.","journal-title":"Pract Neurol"},{"issue":"11","key":"796_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111139","volume":"11","author":"C-C Chang","year":"2021","unstructured":"Chang C-C, Chen Y-K, Chiu H-C, Yeh J-H. Assessment of sarcopenia and obesity in patients with myasthenia gravis using dual-energy X-ray absorptiometry: a cross-sectional study. J Pers Med. 2021;11(11): 1139. https:\/\/doi.org\/10.3390\/jpm11111139.","journal-title":"J Pers Med"},{"key":"796_CR71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1365-2796.1998.00408.x","volume":"244","author":"R Eastell","year":"1998","unstructured":"Eastell R, Reid DM, Compston J, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998;244:271\u201392. https:\/\/doi.org\/10.1046\/j.1365-2796.1998.00408.x.","journal-title":"J Intern Med"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00796-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:22:20Z","timestamp":1758367340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00796-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["796"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00796-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rocco Liguori has received consulting fees, honoraria for lectures or presentation from Maya Idee Sud srl, ISS, Qb Group Srl, Symposium Srl, Accademia Nazionale di Medicina, AIM Italy srl, Aristea Srl and participation to advisory board fees from Argenx; Francesco Habetswallner has received honoraria for lectures or presentation, support for attending meetings or participation to data safety monitoring board\/advisory board fees from Alexion, Argenx, UCB,Roche, Merck, Janssen, Lusofarmaco, Angelini, Abbvie, IPSEN, Alfa Sigma, CLS Boering, Takeda; Michelangelo Maestri has received honoraria for lectures or presentation, support for attending meetings or participation to data safety monitoring board\/advisory board fees from Alexion, Argenx, UCB, Idorsia, Bruno farmaceutica, Italfarmaco; Matteo Gastaldi has received honoraria for lectures or presentation, participation to data safety monitoring board\/advisory board fees UCB, Roche, Alexion, Johnson and Johnson, Argenx; Elena Pegoraro has received consulting fees, honoraria for lectures or presentation from Alexion, UCB, Biogen, Roche, Santhera, Sanofi; Barbara Polistena has received honoraria for lectures or presentation Amgen, Amicus, UCB; Carmelo Rodolico has received support for attending meetings or participation to data safety monitoring board\/advisory board fees from Alexion, Argenx, Johnson & Johnson, UCB Pharma; Giovanni Antonini has received honoraria for lectures or presentation, support for attending meetings or participation to data safety monitoring board\/advisory board fees from Kedrion, Takeda, Alexion, UCB, Alnylam, Argenx. Renato Mantegazza has received support for attending meetings or participation to data safety monitoring board\/advisory board fees from Alexion, Argenx, Johnson & Johnson, UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This consensus statement does not involve human participants, patient data, or interventional research requiring formal ethical approval. The recommendations presented are based on expert opinion and a review of the existing literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}}]}}